Envision Presents Next Generation AI-Powered Smart Glasses for the Blind and Visually Impaired at CSUN 2022

Developed on Google Glass Enterprise Edition 2, Envision Adds Document Guidance and Context, Additional languages, improved accuracy recognition, and 3rd Party Integration to enhance AI Smart Glasses

AI-Powered Smart Glasses: Envision, the award-winning assistive technology innovator, announces a host of advanced features for its acclaimed AI-powered Smart Glasses for the blind and visually impaired.

Available globally and already changing the lives of hundreds of visually impaired people around the world, Envision’s newly launched functionalities include greater Optical Character Recognition (OCR), improved text reading with contextual intelligence, the addition of new languages, and the creation of a third-party app ecosystem allowing the easy integration of specialist services, such as indoor and outdoor navigation, to the Envision platform.

Developed on the Enterprise Edition of Google Glass, Envision made its debut at the 2020 CSUN Conference and is now changing the lives of hundreds of blind and visually impaired people worldwide. It uses artificial intelligence (AI) to extract different kinds of information from images and then speaks the images out loud, enabling blind and low-vision users to read documents at work, recognize their friends, find personal belongings at home, use public transportation, and generally enjoy greater freedom, independence and understanding of the world around them.

“Our mission is to improve the lives of the world’s two billion people who are blind or visually impaired by providing them with life-changing assistive technologies, products and services,” said Karthik Kannan, co-founder of Envision. “By analyzing real-time user data and direct feedback from across our communities, we are able to constantly enrich the Envision experience and innovate our products, most recently with the addition of our new capture and context features. Everyone is entitled to live in a world without boundaries and are thrilled to make Envision Glasses to as many people as possible.”

Envision is available as an iOS and Android App and a sophisticated Google Glass integration. It can read and translate any type of text (digital and handwritten) from any surface (e.g., food packaging, posters, timetables, computer display screens, barcodes etc.) into over 60 different languages. It can recognize faces, objects, and colors and even describe scenes and immediately connect users to trusted contacts through its Ally function – a completely private and secure video call solution built directly into the glasses. You can see it in action here.

Following months of development and advanced AI learning from actual world deployment in over 20 counties, Envision has become even more impactful with significant new features, including:

  • Document Guidance for Accurate Capture – Removes the frustrations of taking multiple images to fully capture a document’s complete text. Enhanced document guidance provides verbal instructions to guide users to position documents to the optimal scanning position allowing capture in a single motion. It means documents can be captured and read in a much timelier and stress-free manner.
  • Layout Detection – Providing a more realistic reading environment, Envision smart glasses will now put a document into context for the reader. Whether a column-based document such as a newspaper, a shop window poster, road sign, or restaurant menu, Envision will decipher the document layout and provide clear verbal guidance to the user. It recognizes headers, photo captions, and more, giving verbal layout context to the user, enabling a more natural flow to the audio read back of the document.
  • Enhanced Offline Language Capabilities– Envision now adds four additional Asian languages, including Hindi, Japanese, Chinese, and Korean, which can be accurately captured and read offline. This addition brings the total of languages supported when offline to 26, with the number of languages supported when connected to more than 60.
  • Third-Party App Development Support – Envision now adds a third-party ecosystem to its platform by allowing developers to build added value services to its users. Launching with the initial partner Cash Reader app, Envision can now recognize banknotes in over 100 currencies.
  • Building Ally — One of the Envision Glasses’ most powerful and popular features is the Ally function that enables a user to ask for assistance or share experiences with trusted contacts (Allys) via completely private video calls directly from the glasses. The new, improved version is optimized for both mobile network and WiFi hotspots providing an unrivaled and unique service that delivers complete peace of mind.
  • Optimizing Optical Character Recognition (OCR) – Leveraging tens of millions of data points processed by the Envision Glasses and Apps has significantly improved image capture and interpretation accuracy.

Envision Glasses are available at a recommended retail price of $3,500 directly from Envision and via its global distributor network.


Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy